What Has Been the Progress and Growth of the Urinary Tract Cancer Market in Recent Years?
The urinary tract cancer market has seen considerable growth due to a variety of factors.
• The market for urinary tract cancer has been experiencing rapid expansion during the recent past. The market will escalate from a value of $3.21 billion in 2024 to $3.87 billion in 2025, representing a compound annual growth rate (CAGR) of 20.6%.
The impressive growth over the historic period is likely due to progress in diagnostic techniques, ongoing pharmaceutical advancements, increased awareness leading to early detection, and advances in precision medicine.
What Can Be Expected from the Urinary Tract Cancer Market Size?
The urinary tract cancer market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated to witness speedy expansion in the forthcoming years, the market for urinary tract cancer is projected to inflate to a worth of $7.74 billion in 2029, escalating at a compound annual growth rate (CAGR) of 18.9%.
This growth momentum during the forecast period is likely to be driven by advancements in immunotherapy, the advent of telemedicine and remote monitoring, research in biomarkers, and adjuvant therapies. The forecast period is also expected to witness significant trends such as international collaboration, progression in palliative care, comprehensive programs for survivorship, and a focus on patient-oriented care.
What Are the Critical Driver Fuelling The Urinary Tract Cancer Market's Growth?
The escalating rate of bladder cancer is projected to catapult the urinary tract cancer market's growth. Bladder cancer involves the formation of cancerous cells in the urinary bladder's tissues, a pelvic hollow organ tasked with retaining urine created by the kidneys until it is excreted by the body. Consequently, the high prevalence escalates the need for diagnostic tools, screening techniques, and treatment alternatives for people diagnosed with urinary tract cancer. For example, in January 2023, the American Cancer Society Inc., a volunteer organization for cancer awareness in the U.S., reported that the calculated figures for urinary system cancer rose to 168,560 in 2023, marking an increase of 2.66% from 164,190 in 2022 in the U.S. As such, the escalating occurrence of bladder cancer will act as a catalyst for the growth of the urinary tract cancer market. The advancement of the urinary tract cancer market is expected to be boosted by an increasing number of urinary tract infection cases. These infections, triggered by bacteria, can affect different components of the urinary system, including the kidneys, bladder, ureters, and urethra. Essential treatment and effective management are required to prevent the spread of the infection, which can ultimately lead to cancer. For instance, in January 2023, the National Institute of Health, an American public health research agency, indicated that urinary tract infections made up the seventh most common ailment that warranted a visit to the emergency department in the U.S., translating to over a million visits annually. Out of these, 22% (220,000) are categorized as complicated UTIs, with about 100,000 admissions observed each year. Therefore, the growing occurrence of urinary tract infections is stimulating the expansion of the urinary tract cancer market.
How Is The Urinary Tract Cancer Market segmented?
The urinary tract cancer market covered in this report is segmented –
1) By Cancer Type: Bladder Cancer, Urethral Cancer, Ureteric And Renal Pelvic Cancer
2) By Treatment: Chemotherapy, Intravesical Therapy, Radiation Therapy, Surgery
3) By Diagnostic Techniques: Cystoscopy, Transurethral Resection Of The Tumor, Imaging Tests, Urine Analyses, Other Diagnostic Techniques
4) By Distribution Channel: Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Bladder Cancer: Transitional Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Other Types
2) By Urethral Cancer: Urethral Carcinoma, Other Urethral Tumors
3) By Ureteric And Renal Pelvic Cancer: Ureteric Cancer, Renal Pelvic Cancer, Other Types
Pre-Book The Urinary Tract Cancer Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Urinary Tract Cancer Market?
Prominent players in the urinary tract cancer market are concentrating their efforts on enhancing the treatment process in order to provide more effective, personalized services and secure a greater market share. These enhancements in the urinary tract cancer treatment sector focus on precision interventions, harnessing the immune system, advancing surgical techniques and customizing treatments to suit each patient’s unique requirements. For instance, UC San Diego Health, an American healthcare system, unveiled a new treatment for patients with low-grade upper tract urothelial cancer (LG-UTUC), a somewhat rare variant of urinary system cancer, in October 2022. This sophisticated treatment offers an alternate solution to the traditional method of total kidney removal, potentially saving patients from future dialysis or kidney transplants. This groundbreaking therapy involves the use of a medicine called Jelmyto, which is administered via a series of injections containing mitomycin, a well-established chemotherapy agent, along with a sterile hydrogel. The drug's administration is guided by injections, allowing for precise targeting of the tumor within the urinary system.
Who Are the Key Players In The Urinary Tract Cancer Market?
Major companies operating in the urinary tract cancer market are:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC (GSK)
• Eli Lilly and Company
• Amgen Inc.
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Boehringer Ingelheim GmbHIncyte Corporation
• Shionogi & Co. Ltd.
• Kyowa Hakko Kirin Co. Ltd.
• Endo International PLC
• Seagen Inc.
• Exelixis Inc.
• Ferring Pharmaceuticals
• Bavarian Nordic
• EUSA Pharma
• UroGen Pharma Inc.
• Mersana Therapeutics
• Protara Therapeutics Inc.
• Spectrum Pharmaceuticals
• IDL Biotech AB
• AroCell AB
• ImmunityBio Inc.
What Is The Most Dominant Region In The Urinary Tract Cancer Market?
North America was the largest region in the urinary tract cancer market in 2024. The regions covered in urinary tract cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
